概括
这项研究表明,婴儿子脏 (BHK) 细胞具有较高的二叶酸减少酶 (DHFR) 水平,具有更多的DHFR信使RNA (mRNA). 这种增加的mRNA数量是这些细胞DHFR升高的主要原因.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 细胞生物学 细胞生物学
背景情况:
- 二叶酸减少酶 (DHFR) 对于细胞增殖至关重要.
- 细胞中甲甲酸耐药性往往与增加的DHFR水平有关.
- 了解DHFR表达的调节是癌症研究的关键.
研究的目的:
- 为了研究甲铁素耐药婴儿仓鼠 (BHK) 细胞中升高的DHFR水平的分子基础.
- 为了确定是否增加DHFR信使RNA (mRNA) 量有助于高DHFR表达.
主要方法:
- 在体外蛋白质合成使用小麦芽提取物和BHK细胞亚系的多体RNA.
- 使用亲和染色学,SDS-PAGE和自发射学识别和确认合成的二叶酸减少酶 (DHFR).
- 用RNA指导的DHFR合成量化,来自对甲状腺素敏感和耐药细胞系.
主要成果:
- 来自BHK细胞的多体RNA指导了在无细胞系统中DHFR的合成.
- 在体外合成的DHFR与真实的BHKDHFR结合,表明类似的分子重量和结构.
- 来自抗甲铁的BHK亚系 (A5) 的RNA指导的DHFR合成大约是来自敏感母亚系 (B1) 的RNA的70倍.
结论:
- 甲基抗BHK细胞中DHFR水平升高主要是由于DHFRmRNA的数量增加.
- 这一发现突显了DHFR基因表达的转录或后转录调节作为药物耐药性的关键机制.
相关概念视频
Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


